Investors purchased shares of Eli Lilly and Co. (NYSE:LLY) on weakness during trading on Thursday. $57.67 million flowed into the stock on the tick-up and $36.52 million flowed out of the stock on the tick-down, for a money net flow of $21.15 million into the stock. Of all companies tracked, Eli Lilly and had the 19th highest net in-flow for the day. Eli Lilly and traded down ($0.33) for the day and closed at $79.78

LLY has been the topic of a number of research reports. Credit Suisse Group AG reiterated a “buy” rating and issued a $91.00 price target on shares of Eli Lilly and in a research note on Wednesday, July 6th. Jefferies Group increased their target price on shares of Eli Lilly and from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, July 14th. TheStreet upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating in a research report on Friday, May 27th. SunTrust Banks Inc. restated a “buy” rating on shares of Eli Lilly and in a research report on Wednesday, June 15th. Finally, Citigroup Inc. restated a “buy” rating on shares of Eli Lilly and in a research report on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $96.35.

The company has a market capitalization of $84.38 billion and a price-to-earnings ratio of 34.39. The company’s 50-day moving average is $80.81 and its 200 day moving average is $75.97.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.86. The business earned $5.40 billion during the quarter, compared to the consensus estimate of $5.14 billion. During the same period last year, the firm earned $0.90 EPS. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. On average, analysts expect that Eli Lilly and Co. will post $3.59 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be given a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 2.56%. The ex-dividend date of this dividend is Thursday, August 11th.

In other news, insider Donald A. Zakrowski sold 1,213 shares of the business’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the sale, the insider now owns 1,300 shares of the company’s stock, valued at $108,108. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Melissa S. Barnes sold 992 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $73.77, for a total transaction of $73,179.84. Following the completion of the sale, the senior vice president now directly owns 10,710 shares in the company, valued at approximately $790,076.70. The disclosure for this sale can be found here.

Several hedge funds have bought and sold shares of LLY. Schwab Charles Investment Management Inc. raised its stake in Eli Lilly and by 3.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 3,586,902 shares of the company’s stock valued at $302,233,000 after buying an additional 129,362 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in Eli Lilly and by 45.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 87,000 shares of the company’s stock valued at $7,331,000 after buying an additional 27,275 shares during the period. King Luther Capital Management Corp raised its stake in Eli Lilly and by 1.4% in the fourth quarter. King Luther Capital Management Corp now owns 186,246 shares of the company’s stock valued at $15,693,000 after buying an additional 2,562 shares during the period. Budros Ruhlin & Roe Inc. raised its stake in Eli Lilly and by 0.4% in the fourth quarter. Budros Ruhlin & Roe Inc. now owns 27,156 shares of the company’s stock valued at $2,288,000 after buying an additional 121 shares during the period. Finally, Calvert Investment Management Inc. raised its stake in Eli Lilly and by 24.1% in the fourth quarter. Calvert Investment Management Inc. now owns 51,507 shares of the company’s stock valued at $4,340,000 after buying an additional 10,005 shares during the period.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.